DNA sequencing
The Oncomine™ Focus Assay (Thermofisher.com) is a next-generation sequencing panel that includes 52 genes associated with solid tumors that can be targeted by drugs.
Genes analysed for the presence of SNVs include: AKT1, ALK, AR, BRAF, Cdk4, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR2, FGFR3, GNA11, GNAQ, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, PDGFRA, PIK3CA, RAF1, RET, ROS1, SMO.
Gene potentially subjected to CNAs include: ALK, AR, BRAF, CCND1, Cdk4, Cdk6, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, FGFR4, KIT, KRAS, MET, MYC, MYCN, PDGFRA, PIK3CA.
Genes candidate for fusions include: ALK, RET, ROS1, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, FGFR3, MET, BRAF, RAF1, ERG, ETV1, ETV4, ETV5, ABL1, AKT3, AXL, EGFR, ERBB2, PDGFRA, PPARG.
NGS data analysis
For the identification of SNVs and small indels, the IR 5.0 integrated the Torrent Variant Caller (TVC) algorithm optimized for sequencing data obtained on the Ion Torrent platform. The automated pipeline of IR 5.0 filters SNVs for quality, coverage, strand bias and signal shift. All SNVs called as positive were covered at least 400X.
The CNV calling Algorithm in IR 5.0 makes use of the Median of the Absolute values of all Pairwise Differences (MAPD) between log2 ratios per tile for a given run to give a measurement of noise and/or other errors. The observed difference is due to CNVs (all CNV reported presented a MAPD value < 0.4).
The fusion analysis pipeline processes 3 input files (an uBAM file, a fusion reference Fasta file comprising chimeric sequences for targeted fusion transcripts and control targets, a target bed file that includes information about fusion breakpoint, expression controls and target assays. The algorithm processes the input files in order to extract read counts for fusion and expression controls. Parameters set to obtain accurate imbalance determinations were: a threshold of 40,000 total reads/ sample, presence of >4 out of 5 expression controls and >20 reads for a specific fusion.
Primers used for fusion validation
The primers for RT-PCR in validation of MET exon 14 skipping were as follows:
FW, 5′-CTT CAA CCG TCC TTG GAA AA -3′; REV, 5′-CCTATGACTTCATTGAAATGCAC -3′. The primers used for RT-PCR in validation of FGFR3-TACC3 fusion were as follows: G14  M  81  T1b  N1  M0  G2  Intestinal  IB   G15  M  48  T1  N0  M0  G1  Intestinal  I   G16  M  77  T2a  N0  M0  G2  Intestinal  I   G17  F  72  T1  N0  M0  G3  Diffuse  I   G18  M  75  T3  N3  M0  G3  Poorly Differentiated  IV   G19  M  54  T2  N1  M0  G3  Intestinal  II   G20  M  72  T2  N3  M1  G3  Signet ring cell carcinoma  IV   G21  M  64  T3  N3  M1  G3  Poorly Differentiated  IV   G22  M  82  T3  N0  M0  G3 Intestinal II T4a  N2a  MX  G2   CC17  F  84  Splenic Flexure  T3  N1  M0  G2   CC18  M  79  Descending Colon  T3  N0  M0  G2   CC19  M  56  Descending Colon  T4  N1a  M0  G3   CC20  F  86  Ascending Colon  T3  N0  M0  G2   CC21  M  71  Descending Colon  T3  N0  M0  G2   CC22  F  67  Descending Colon  T3  N1B  MX  G2   CC23  M  68  Descending Colon  T3  N0  M0  G3   CC24  M  56  Descending Colon  T2  N0  MX  G2   CC25  F  56  Descending Colon  T4  N0  M0  G3   CC26  F  46  Descending Colon  T4  N1b  M0  G3   CC27  F  89  Descending Colon  T3  N1b  M0  G3   CC28  M  Ascending Colon  T3  N1b  M1  G2   CC29  F  84  Descending Colon  T4b  N0  M1  G2   CC30  F  85  T4a  N1b  M1  G2   CC31  F  70  Descending Colon  T4  N2a  M1  G3 M  81  T3  N0  M0  G3   RC19  F  81  T2  N0  Mx  G2   RC20  M  59  T4b  N1  M0  G3   RC21  F  69  T2  N0  Mx  G2   RC22  F  60  NA  NA  NA  NA   RC23   RC24  F 
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